Pharmaceutical - LCZ696

Filter

Current filters:

LCZ696

Popular Filters

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

28-11-2014

Swiss drug major Novartis announced that the European Medicines Agency’s Committee for Medicinal Products…

Cardio-vascularEuropeLCZ696NovartisPharmaceuticalRegulation

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

18-11-2014

New data on Swiss drug major Novartis’ investigational medicine LCZ696, for patients with heart failure…

Cardio-vascularLCZ696NovartisPharmaceuticalResearchSwitzerland

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

31-08-2014

Swiss drug major Novartis on Saturday presented striking new data for its LZC696 heart drug at the European…

Cardio-vascularLCZ696NovartisPharmaceuticalRegulationResearch

Novartis halts Ph III LCZ696 trial on strong results

Novartis halts Ph III LCZ696 trial on strong results

31-03-2014

Swiss drug major Novartis says that the Data Monitoring Committee (DMC) unanimously recommended early…

Cardio-vascularLCZ696NovartisPharmaceuticalResearch

Modest growth forecast for global CD market

02-12-2013

The global market for cardiovascular disease - comprised of heart failure, myocardial infarction and…

AstraZenecaAZD6140BAY81-8781BayerCardio-vascularLCZ696Markets & MarketingNovartisPharmaceuticalPricingserelaxin

Back to top